Tag: Immunotherapy
Hyperimmune Globulin Does Not Prevent Congenital CMV Infection
Cytomegalovirus hyperimmune globulin does not lower incidence of composite of congenital CMV infection, perinatal death in offspring
Immunomodulation With IVIG, Glucocorticoids Examined in MIS-C
Early outcomes of two large observational studies show mixed results for the efficacy of immunomodulation with IVIG, glucocorticoids, or both
VTE Risk High in Cancer Patients Receiving Immune Checkpoint Inhibitors
History of VTE predicts VTE occurrence; VTE occurrence linked to increased mortality
FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum-containing chemotherapy treatment
Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy
Cutaneous immune-related adverse events seen in 25 percent of cancer patients initiating ICI therapy with median onset time of 113 days
Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
About 43 percent of patients who receive anti-PD1 therapy for advanced melanoma have chronic immune-related adverse effects
Broadly Neutralizing Antibodies Do Not Prevent Overall HIV-1 Acquisition
Analysis of pooled data from proof-of-concept trials shows bnAb VRC01 does reduce incidence of infection with VRC01-sensitive isolates
Early Immunologic Biomarker Predicts Renal Allograft Outcomes
Ratio of IL-10/TNFα produced by T1B three months after renal transplantation predicts clinical, subclinical rejection during first year
Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma
FMT plus anti-PD-1 therapy may change gut microbiome and help overcome drug resistance in some patients with advanced melanoma
SARS-CoV-2 Infection Rate Low in Patients Receiving Antitumor Therapy
Less than 1 percent of patients receiving antitumor treatment between Jan. 15 and May 4, 2020, developed COVID-19
